Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neuroone Medical Technologies (NMTC) Shares Outstanding (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Shares Outstanding readings, the most recent being $8.6 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 64.71% to $8.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.6 million, a 64.71% increase, with the full-year FY2025 number at $8.3 million, up 62.28% from a year prior.
  • Shares Outstanding hit $8.6 million in Q1 2026 for Neuroone Medical Technologies, up from $8.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $49.8 million in Q2 2025 to a low of $5.1 million in Q3 2024.
  • Median Shares Outstanding over the past 5 years was $16.2 million (2022), compared with a mean of $17.2 million.
  • The widest YoY moves for Shares Outstanding: up 78.93% in 2025, down 80.13% in 2025.
  • Neuroone Medical Technologies' Shares Outstanding stood at $16.2 million in 2022, then skyrocketed by 52.92% to $24.8 million in 2023, then tumbled by 79.3% to $5.1 million in 2024, then soared by 63.46% to $8.4 million in 2025, then grew by 2.54% to $8.6 million in 2026.
  • The last three reported values for Shares Outstanding were $8.6 million (Q1 2026), $8.4 million (Q4 2025), and $8.3 million (Q3 2025) per Business Quant data.